News | February 04, 2013

Biotronik Launches the 3Flow Aspiration Catheter for Improved Thrombus Aspiration

The catheter’s features, which include one of the market’s largest extraction lumen and locking syringe, allow for quick, easy and accurate thrombus aspiration

3Flow Aspiration Catheter Thrombectomy Devices Biotronik Inc. Europe

February 4, 2013 — Biotronik recently launched its 3Flow Aspiration Catheter in Europe. The catheter is specifically designed to facilitate quick and accurate thrombus aspiration, complementing Biotronik’s already broad coronary vascular intervention (CVI) portfolio.

Thrombus aspiration is applicable in a larger majority of patients with myocardial infarction with ST-segment elevation (STEMI). Acute ST-segment elevation indicates that a relatively large amount of heart muscle damage is occurring because thrombus occludes an epicardial artery. Thrombus aspiration significantly improves the clinical outcome in STEMI patients and has received a IIa recommendation in the most recent ESC guidelines (European Society of Cardiology).

The 3Flow Catheter’s features differentiate it from other catheters on the market: With the supplied 60ml locking syringe and large inner lumen, the 3Flow Catheter allows for the extraction of larger thrombotic particles — as well as for a longer aspiration time. Its hydrophilic distal coating and smooth tip design furthermore ensure that excellent deliverability and optimal kink resistance are provided by the proximal high performance thermoplastic polymer shaft.

“The large syringe doubles the aspiration time compared to standard 30 mL syringes, which avoids switching syringes in many cases and allows to better focus on the accuracy of the procedure,” says Dr. Henrik Schneider from the University Hospital in Rostock, Germany. “At the same time, the large inner lumen catheter allows for aspiration of larger thrombotic particles and causes less blockages.”

“For STEMI patients, 3Flow is an ideal extension to our stent and balloon portfolio. In this very critical patient segment, a proper lesion preparation is as always key to successful stenting”, says Alain Aimonetti, vice president sales and business development, Biotronik Vascular Intervention. 


Related Content

News | Thrombectomy Devices

Nov. 3, 2025 — Penumbra, Inc. has announced additional results of the STORM-PE randomized controlled trial (RCT), which ...

Home November 07, 2025
Home
News | Thrombectomy Devices

Oct. 27, 2025 – Penumbra, Inc. has announced the results of the STORM-PE randomized controlled trial (RCT), which found ...

Home October 27, 2025
Home
News | Thrombectomy Devices

Sept. 2, 2025 — Imperative Care, Inc. has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its ...

Home September 02, 2025
Home
News | Thrombectomy Devices

June 16, 2025 – Penumbra, Inc. recently announced the completion of enrollment in the STORM-PE clinical trial. This ...

Home June 16, 2025
Home
News | Thrombectomy Devices

March 24, 2025 — Imperative Care, Inc. recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ...

Home March 24, 2025
Home
News | Thrombectomy Devices

Penumbra recently launched its Element Vascular Access System, a laser-cut hypotube sheath designed for venous ...

Home January 30, 2025
Home
News | Thrombectomy Devices

Nov. 5, 2024 —Penumbra, Inc. recently announced new data that demonstrate patients with intermediate-risk pulmonary ...

Home November 07, 2024
Home
News | Thrombectomy Devices

Sept. 24, 2024 — Thrombolytic Science, LLC (TSI) has announced that the U.S. Food and Drug Administration (FDA) has ...

Home September 24, 2024
Home
News | Thrombectomy Devices

Sept. 5, 2024 - Prolocor, Inc. and Slingshot Biosciences recently announced the publication in Bioanalysis of the ...

Home September 10, 2024
Home
News | Thrombectomy Devices

January 16, 2024 — Penumbra, Inc., a thrombectomy company, has recently secured CE Mark (Conformité Européenne) for its ...

Home January 16, 2024
Home
Subscribe Now